Monday, February 26, 2024
In the United States, where more than 100 million people are affected by various liver diseases but only 4.5 million have been diagnosed, Echosens, a leader in liver health, introduces its latest innovation: Guided Vibration-Controlled Transient Elastography (VCTE)™ technology, exclusive to new FibroScan® systems. As liver disease rates continue to rise, the launch of this groundbreaking FibroScan® system addresses the critical need for precise, non-invasive liver assessment, catering to healthcare professionals dedicated to patient care. With one in ten individuals now at risk globally, increasing screening rates is imperative to prevent a potential surge in liver disease diagnoses.
This cutting-edge technology plays a pivotal role in combatting the rise of metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH) in the United States. Leveraging Echosens' diagnostic expertise, Guided VCTE offers accurate liver stiffness measurements, a vital fibrosis marker, facilitating rapid, non-invasive evaluations across diverse patient demographics.
Patients benefit from expedited assessments, reducing anxiety and discomfort, while healthcare professionals experience improved diagnostic speed and workflow. Key features of Guided VCTE include:
This advancement represents a significant step forward in simplifying liver disease diagnosis and management, making liver assessments more accessible and seamlessly integrated into practices than ever before.
Source: prnewswire.com
